Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Capria, Saveria, Trisolini, Silvia Maria, Minotti, Clara, Stefanizzi, Caterina, Cardarelli, Luisa, Cartoni, Claudio, Diverio, Daniela, De Propris, Maria Stefania, Mancini, Marco, Micozzi, Alessandra, Foà, Robin, Meloni, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507532/
https://www.ncbi.nlm.nih.gov/pubmed/23205260
http://dx.doi.org/10.4084/MJHID.2012.072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507532/
https://www.ncbi.nlm.nih.gov/pubmed/23205260
http://dx.doi.org/10.4084/MJHID.2012.072

Ejemplares similares